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Introduction
Juvenile dermatomyositis (JDM) is an autoimmune disease
characterized by proximal muscle weakness and cutaneous
manifestations, typically heliotrope rash and Gottron’s
papules. Previous studies have identified an increase in cir-
culating B cells in JDM patients, but their provenance and
functional characteristics have not been examined. In this
study we investigated whether a recently identified imma-
ture B cell subset (CD24hiCD38hi) with known regulatory
function (Breg) was enriched in JDM and correlated with
disease outcome measures.
Objectives
To characterize the peripheral blood B cell compart-
ment in JDM patients, both before and after treatment,
and assess the production of the B cell immunoregula-
tory cytokine, IL-10, in 45 patients recruited through
the UK JDM Cohort and Biomarker Study.
Methods
B cell subpopulations from peripheral blood mononuc-
lear cells (PBMC) isolated from healthy controls (HC)
and JDM patients were analyzed by flow cytometry
using the surface markers CD19, CD24, CD38, CD27,
IgM, and IgD. PBMC were stimulated for 72 hours with
CD40 ligand (CD40L) transfected CHO cells, together
with PMA and ionomycin for the last 5 hours in the
presence of Brefeldin A. Cells were then stained for
CD19 and intra-cellular IL-10 which was detected by
flow cytometry.
Results
Ex-vivo analysis of pre-treatment (pre-Rx) JDM PBMC
displayed a significant increase in CD19+ B cells when
compared to post-Rx JDM samples (mean of 25.8% to
16.1%, p = 0.012). The immature B cell compartment
was expanded in pre-Rx JDM patients (mean of 28.3% vs
12.3% in post-Rx, p = 0.0019). Moreover, this B cell
expansion correlated with the severity of clinical disease
(Physician’s global assessment vs B cell frequency, R =
0.38). Following stimulation with CD40L, a lower propor-
tion of B cells from JDM patients expressed IL-10 than
aged matched controls (mean of 16.3% vs 18.9% respec-
tively). JDM patients receiving corticosteroid treatment
showed a trend for a higher frequency of CD40L induced
IL-10+ B cells (mean 19.5% vs 14.4%, p = 0.12).
Conclusion
These data identify an expansion of immature B cells in
JDM patients at disease presentation. Although phenoty-
pically similar to Breg, B cells from JDM patients did
not match the induction of IL-10 seen in child controls.
Ongoing work will test the hypothesis that Breg are





1Centre for Rheumatology, Division of Medicine, University College London,
UK. 2Rheumatology Unit, UCL Institute of Child Health, London, UK.
1Centre for Rheumatology, Division of Medicine, University College London,
UK
Full list of author information is available at the end of the article
Piper et al. Pediatric Rheumatology 2013, 11(Suppl 2):O3
http://www.ped-rheum.com/content/11/S2/O3
© 2013 Piper et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-O3
Cite this article as: Piper et al.: PReS-FINAL-1020: Dysregulation of the
peripheral blood D cell compartment is associated with disease activity
in juvenile dermatomyositis. Pediatric Rheumatology 2013 11(Suppl 2):O3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Piper et al. Pediatric Rheumatology 2013, 11(Suppl 2):O3
http://www.ped-rheum.com/content/11/S2/O3
Page 2 of 2
